Teva reveals critical Ajovy data
Therapy has been developed to reduce the frequency, duration and severity of migraine attacks
Read Moreby John Pinching | Jul 4, 2023 | News | 0
Therapy has been developed to reduce the frequency, duration and severity of migraine attacks
Read Moreby Selina McKee | Jul 21, 2020 | News | 0
Teva’s new device allows migraine sufferers to self-administer the drug
Read Moreby Selina McKee | Jun 4, 2020 | News | 0
One in seven UK adults is affected by migraine
Read Moreby Anna Smith | Mar 12, 2020 | News | 0
The anti-CGRP preventive therapy is the first of-its-kind to be recommended by NICE.
Read Moreby Anna Smith | Jan 14, 2020 | News | 0
The group also accepted drugs for primary progressive multiple sclerosis and a rare form of lymphoma.
Read Moreby Anna Smith | Jul 30, 2019 | News | 0
Teva recently halted its Ajovy clinical development.
Read Moreby Anna Smith | Apr 24, 2019 | News | 0
A Phase III study found that the primary endpoint for weekly average number of cluster headache attacks during the four-week treatment period is unlikely to be met.
Read Moreby Anna Smith | Apr 2, 2019 | News | 0
The drug is a pre-filled syringe for the prophylaxis of migraine in adults who have at least four migraine days per month.
Read Moreby Selina McKee | Sep 17, 2018 | News | 0
US regulators have approved Teva’s Ajovy for the preventative treatment of migraine in adults.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
